Neurelis, Inc.

32 articles with Neurelis, Inc.

• Neurelis Announces Acquisition Of Rights To Portfolio Of New Chemical Entity (NCE) Compounds Targeting Cerebral Cavernous Malformations, A Rare CNS Disorder

  6/21/2021

  Neurelis, Inc., announced today that it has acquired from BioAxone Biosciences, Inc.

• Neurelis Announces Five Poster Presentations for the Annual Meeting of the American Academy Of Neurology

  4/19/2021

  Neurelis, Inc., announced today that it is presenting five posters at the American Academy of Neurology (AAN) Annual Meeting being held virtually from April 17 through April 22. 

• Neurelis Announces Two Poster Presentations for the Annual Meeting of the Academy of Managed Care Pharmacy

  4/12/2021

  Clinical studies support effectiveness and safety profile for Neurelis' lead product, VALTOCO® (diazepam nasal spray), the first and only nasal spray treatment for seizure cluster rescue in adult and pediatric patients 6 years of age and older

• 

  Money on the Move: March 10-16

  3/17/2021

  Life sciences money is seemingly growing on trees this year. Here's who picked a good harvest this week.

• Neurelis Announces Close Of $114 Million Series D Financing Round To Advance Neuroscience Focus

  3/10/2021

  - 2021 financing will be a catalyst to further establish Neurelis as a best-in-class epilepsy company - Funds will enhance growth and commercial penetration of company's lead orphan drug product, VALTOCO® (diazepam nasal spray), and support pipeline development and expansion - Company also announces appointment of healthcare industry expert Alexander Kwit to its Board of Directors

• Neurelis Announces 12 Poster Presentations For The Annual Meeting Of The American Epilepsy Society

  12/4/2020

  Neurelis, Inc., announced today the company has 12 posters being presented at the American Epilepsy Society Annual Meeting being held virtually from December 4 through December 8.

• Neurelis Completes Pre-IND Meeting With FDA to Establish Clinical Development Program for NRL-4 in the Treatment of Acute Agitation Associated With Schizophrenia and Bipolar 1 Mania in Adults

  11/23/2020

  Neurelis, Inc., announced today that it has concluded a pre-Investigational New Drug (IND) Application meeting with the U.S. Food and Drug Administration (FDA) regarding NRL-4.

• Neurelis Announces National Wholesale And Retailer Chains And Independent Pharmacies Are Now Stocking VALTOCO® (Diazepam Nasal Spray)

  11/9/2020

  Neurelis, Inc., announced today that the company's lead product, VALTOCO® (diazepam nasal spray), is now available through pharmacies nationwide

• Neurelis Announces FDA Approval Of Extended Expiration Dating For VALTOCO® (Diazepam Nasal Spray)

  10/19/2020

  Neurelis, Inc. announced today that the U.S. Food and Drug Administration (FDA) has granted extended expiration dating for the company's lead product, VALTOCO ® (diazepam nasal spray). VALTOCO was approved by the FDA on January 10, 2020 , for the acute treatment of intermittent, stereotypic episodes of frequent seizure activity (ie, s

• Neurelis Announces Four Poster Presentations For The Joint Meeting Of The International Child Neurology Association And Child Neurology Society

  10/16/2020

  - Data continue to support the unique clinical attributes for Neurelis' lead product, VALTOCO® (diazepam nasal spray), the first and only nasal spray treatment for seizure cluster rescue in pediatric patients 6 years of age and older, adolescents, and adults - Data also highlight that 88 percent of treated seizure episodes used a single dose of VALTOCO

• Neurelis Announces Program To Investigate The Safety And Pharmacokinetics Of VALTOCO® (Diazepam Nasal Spray) In Children Aged 2 To 5

  9/23/2020

  Neurelis, Inc., announced today that it will be investigating the safety and pharmacokinetics of the company's lead product, VALTOCO® (diazepam nasal spray), in children with epilepsy aged two to five.

• Neurelis Announces Rapid and Broad Payer Coverage of the Company's Flagship Product, VALTOCO® (Diazepam Nasal Spray)

  6/8/2020

  - More than 176 million lives in the U.S. now covered by payers/managed care/insurance plans within months of FDA approval of VALTOCO, the first and only nasal spray treatment of seizure clusters in patients 6 years of age and older - Neurelis' patient assistance program supports eligible patients who have no health insurance - Co-pay program for VALTOCO helps commercial patients lower their out-of-pocket costs to as low as $20  

• Neurelis Announces Total Of Nine Poster Presentations For The AANN, AMCP, And AAN Annual Meetings

  5/20/2020

  - Data supports pharmacokinetic and safety profile for Neurelis' lead product, VALTOCO® (diazepam nasal spray), the first and only nasal spray treatment for seizure cluster rescue in pediatric patients 6 years of age and older, adolescents, and adults - Data also further highlights the permeation enhancer potency of Intravail® for both small and large molecules; Intravail is a key component of VALTOCO formulation   [20-May-2020]

• Neurelis Announces That Intravail® Licensee, ARS Pharmaceuticals' Intranasal Epinephrine Product, Demonstrates Bioequivalent Exposure To Epinephrine Injectors

  5/4/2020

  - ARS Pharmaceuticals' lead product, ARS-1 (epinephrine nasal spray) to treat severe allergic reactions, has previously been granted Fast Track designation by the U.S. Food and Drug Administration (FDA) - Neurelis' lead product, VALTOCO® (diazepam nasal spray), approved by the FDA for seizure cluster rescue, also utilizes Intravail® as a key component of its formulation - New data further highlight the permeation enhancement potency of Intravail® for both small and large mole

• Neurelis Announces Commercial Availability of VALTOCO® (Diazepam Nasal Spray) for Seizure Cluster Rescue

  3/2/2020

   Neurelis, Inc., announced today the commercial availability of VALTO for the acute treatment of intermittent, stereotypic episodes of frequent seizure activity.

• Neurelis To Present At SVB Leerink 9th Annual Global Healthcare Conference

  2/24/2020

  SAN DIEGO , Feb. 24, 2020 /PRNewswire/ -- Neurelis, Inc., today announced that the company will be participating in the SVB Leerink 9 th Annual Global Healthcare Conference at Lotte New York Palace, New York City.  Neurelis President and CEO Craig Chambliss will present at 2:15 pm EST on Tuesday , February 25.  About Neurelis

• Neurelis Announces FDA Approval for Seizure Rescue Treatment VALTOCO® (Diazepam Nasal Spray) that Incorporates the Science of Intravail® for Consistent and Reliable Absorption

  1/13/2020

  VALTOCO (diazepam nasal spray) is approved by the U.S. Food and Drug Administration (FDA) for use by a care partner outside of the medical setting for the acute treatment of intermittent, stereotypic episodes of frequent seizure activity (i.e., seizure clusters, acute repetitive seizures) that are distinct from a patient's usual seizure pattern

• Neurelis Announces Nine Poster Presentations At The Annual Meeting Of The American Epilepsy Society

  12/5/2019

  Neurelis' investigational product candidate, VALTOCO® (diazepam nasal spray), currently under review by the U.S. Food and Drug Administration

• Neurelis Announces Three Poster Presentations At The Annual Meeting Of The Child Neurology Society

  10/22/2019

  Neurelis' investigational product candidate, VALTOCO® (diazepam nasal spray), currently under review by the U.S. Food and Drug Administration

• Neurelis Announces Two Poster Presentations At The Annual Meeting Of The American Academy Of Neurology

  4/29/2019

  Neurelis' lead product candidate for seizures, VALTOCO™ (diazepam nasal spray), currently under FDA review